TELONasdaq

Telomir Pharmaceuticals, Inc.

Healthcare·Oncology·Phase 1·Miami, FL, United States
Oncology

Telomir Pharmaceuticals, Inc. (TELO): 2 pipeline candidates · 1 clinical trial. Updated within the last hour.

6.8/10

BioSniper Score

3-factor signal · derived from public data

Cash RunwayN/A

N/A

Financial Health9.7

D/E 0.17 · 0% dilution

Pipeline Maturity6.0

Lead: Phase 1/Phase 2

Pipeline Breadth4.6

2 candidates

Catalyst MomentumN/A

N/A

Insider SignalN/A

N/A

A transparent, data-derived signal for Telomir Pharmaceuticals, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.

Key Financials

Market Cap

$91.1M

Cash

Quarterly Burn

$1.8M

Runway

Revenue

Pipeline (2 candidates)

DrugPhase
telomir-1Phase 1/Phase 2
zn-telomirPhase 1/Phase 2

Institutional Holdings

Source: SEC Form 13F · as of Mar 2026

Institutional holders

25

Total value held

$4.1M

HolderSharesValue
vanguard capital management llc1,990,746$2.6M
blackrock, inc.289,198$376K
geode capital management, llc249,086$324K
vanguard fiduciary trust co135,541$176K
millennium management llc129,060$168K
state street corp58,600$76K
bank of new york mellon corp51,454$67K
northern trust corp41,844$54K
xtx topco ltd36,061$47K
osaic holdings, inc.35,795$47K

Showing top 10 of 25 institutional holders of Telomir Pharmaceuticals, Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.

1 clinical trial·1 FDA decision·CEO: Mr. Erez Aminov

Frequently asked questions

How many drug candidates are in Telomir Pharmaceuticals, Inc.'s pipeline?

Telomir Pharmaceuticals, Inc. (TELO) has 2 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.

What is Telomir Pharmaceuticals, Inc.'s lead drug candidate?

Telomir Pharmaceuticals, Inc.'s most advanced tracked candidate is telomir-1 (Phase 1/Phase 2) for Oncology.

What is Telomir Pharmaceuticals, Inc.'s market capitalization?

Telomir Pharmaceuticals, Inc.'s market capitalization is approximately $91.1M.

Who is the CEO of Telomir Pharmaceuticals, Inc.?

Mr. Erez Aminov is the chief executive officer of Telomir Pharmaceuticals, Inc. (TELO).

Get the full picture on Telomir Pharmaceuticals, Inc.

Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.